BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18089332)

  • 1. Feasibility of C2 monitoring in Korean renal transplantation.
    Park JB; Han YS; Kim SJ; Choi GS; Kwon CH; Lee SK; Kim DJ; Joh JW
    Transplant Proc; 2007 Dec; 39(10):3105-8. PubMed ID: 18089332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis.
    Internation Neoral Renal Transplantation Study Group
    Am J Transplant; 2002 Feb; 2(2):157-66. PubMed ID: 12099518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
    Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
    Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation].
    Vavić N; Ignjatović L; Drasković B; Hrvacević R; Kovacević Z; Paunić Z
    Vojnosanit Pregl; 2008 Feb; 65(2):119-27. PubMed ID: 18365668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation.
    Wacke R; Kundt G; Gock M; Klar E; Drewelow B; Schareck W
    Transplant Proc; 2006 Apr; 38(3):751-2. PubMed ID: 16647462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M
    J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U; Ullrich S; Roskos M; Misselwitz J
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine C2 levels in de novo renal allograft recipients: a German multicenter prospective observational study.
    Arns W; Zantvoort F; Abendroth D; Seiter H; Scheuermann EH; Albert U; Stahl R; Fornara P; Fricke L; Neumayer HH; Nagel E; Michel U; Ulbricht B
    Transplant Proc; 2005 Apr; 37(3):1612-5. PubMed ID: 15866687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of C0 and C2 cyclosporine monitoring in long-term renal transplant recipients.
    Marcén R; Pascual J; Tato A; Villafruela JJ; Teruel JL; Rivera ME; Tenorio M; Fernández M; Burgos FJ; Ortuño J
    Transplant Proc; 2003 Aug; 35(5):1780-2. PubMed ID: 12962793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P; Ortiz AM; Jara A; Vilches S
    Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection.
    Weber LT; Armstrong VW; Shipkova M; Feneberg R; Wiesel M; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B;
    Ther Drug Monit; 2004 Aug; 26(4):415-24. PubMed ID: 15257072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
    Bunnag S; Vareesangthip K; Ong-ajyooth L
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-hour post-dose cyclosporine levels in renal transplantation in Argentina: a cost-effective strategy for reducing acute rejection.
    Balshaw R; Machnicki G; Carreño CA; Toselli L; Otero A; Keown PA
    Transplant Proc; 2005 Mar; 37(2):871-4. PubMed ID: 15848560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
    J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations.
    Brunet M; Millán O; Jiménez O; Campistol JM; Vidal E; Rojo I; Oppenheimer F; Fortuna V; Martorell J
    Transplant Proc; 2004 Mar; 36(2 Suppl):437S-441S. PubMed ID: 15041382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.